Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

Cigna Group shares fell sharply after the health insurer reported fourth-quarter profit that was dragged down by medical ...

The first medical marijuana conference in Bordeaux, France, featuring doctors, scientists, and entrepreneurs from the UK and ...

The Crafoord Prize in Polyarthritis 2025, worth 6 million Swedish kronor, is awarded to Christopher Goodnow, Australia, and David Nemazee, USA. They ...

Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

Roche Holding AG said profit will probably outpace sales growth this year as the Swiss drugmaker works to keep research costs in check and looks for deals to build its pipeline of experimental ...

Oppenheimer initiated coverage on Alumis Inc (NASDAQ:ALMS) with an Outperform rating and a price target of $32.00. The firm's analysts highlighted the biopharmaceutical company's focus on developing ...

ECTRIMS and EBMT said stem cell transplant can be considered for some with RRMS, such as those who are younger and have less severe disease.

Intranasal foralumab can modulate a number of immune cell types in people with non-active SPMS, developer Tiziana Life ...

After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year on the market. | After repeatedly wowing investors, Roche’s star eye med ...

The pause has potentially left the public in the dark about updates to scientific research and public health issues like flu outbreaks ...